Healthcare

HHS Drug Testing Panel Guidelines

The Department of Health and Human Services (HHS) has issued updated guidelines for authorized drug testing panels used in federal workplace drug testing programs. The current drug testing panels for urine and oral fluid, along with the required nomenclature for laboratory and Medical Review Officer Reports, remain in effect as of July 7, 2025, with minor edits to footnotes for clarity.

Strattera Oral Solution SMPC Posting

The FDA has posted the Summary of Product Characteristics (SMPC) for Strattera oral solution on March 13, 2026. This posting provides updated information regarding the drug's characteristics and usage. It is intended for informational purposes for drug manufacturers and healthcare professionals.

FDA Acknowledgment Letter to Athyna Pharma

The FDA's Center for Drug Evaluation and Research (CDER) has issued an acknowledgment letter to Athyna Pharma, LLC. This notice confirms receipt of a submission from the company.

FDA Approves Labeling for RLD, NDA N021411

The FDA has approved labeling for RLD (Reference Listed Drug) and NDA (New Drug Application) N021411. This notice indicates a regulatory action related to drug approval and labeling requirements.

FDA Approves Labeling for RS, ANDA 202682

The U.S. Food and Drug Administration (FDA) has approved labeling for RS, as indicated by ANDA 202682. This approval was posted on March 13, 2026, and pertains to specific drug product labeling.

FDA Acknowledgment Letter to Irish Multimedia, LLC

The FDA has issued an acknowledgment letter to Irish Multimedia, LLC regarding a submission. The letter confirms receipt of the submission but provides no substantive details on its content or purpose.

FDA Acknowledgment Letter to Special FX Rentals

The FDA's Center for Devices and Radiological Health (CDRH) has issued an acknowledgment letter to Special FX Rentals. This notice confirms receipt of documentation and does not indicate approval or disapproval of any submissions.

FDA Variance Approval Letter

The FDA has issued a variance approval letter to Richard Lathrop, authored by CDRH. The letter, which contains restricted personally identifiable information, has been redacted and is available for download.

FDA Document Details

The Food and Drug Administration (FDA) has published details for a new document on regulations.gov. This notice provides access to the document and its associated information for interested parties. Further details regarding the document's content are available via the provided URL.

FDA Natural Family Planning Curricula Background Material

The FDA has posted background material related to Natural Family Planning curricula. This notice provides informational resources for interested parties.